NASDAQ · CARL
Healthcare · Medical - Healthcare Information Services
$13.99
Up+$0.27 (+1.97%)
Updated Aug 14, 2026, 10:26 AM
SID Score
5.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
CARL closed at $13.99 after 21 trading sessions, up 18.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $13.87 | $14.16 | $13.77 | $13.99 | 127.4K |
| Aug 12, 2026 | $13.67 | $14.02 | $13.30 | $13.72 | 150.07K |
| Aug 11, 2026 | $13.76 | $13.88 | $13.44 | $13.73 | 86.64K |
| Aug 10, 2026 | $13.71 | $14.03 | $13.53 | $13.73 | 78.1K |
| Aug 7, 2026 | $13.70 | $14.05 | $13.67 | $13.82 | 95.92K |
| Aug 6, 2026 | $13.90 | $15.17 | $13.45 | $13.70 | 425.51K |
| Aug 5, 2026 | $13.45 | $13.63 | $12.90 | $13.56 | 171.76K |
| Aug 4, 2026 | $12.78 | $13.70 | $12.78 | $13.43 | 160.54K |
| Aug 3, 2026 | $12.92 | $13.405 | $12.79 | $12.93 | 199.02K |
| Jul 31, 2026 | $12.66 | $12.8727 | $12.31 | $12.59 | 79.66K |
| Jul 30, 2026 | $12.56 | $13.00 | $12.37 | $12.66 | 126.06K |
| Jul 29, 2026 | $12.28 | $13.015 | $12.05 | $12.78 | 138.19K |
| Jul 28, 2026 | $11.54 | $12.535 | $11.54 | $12.31 | 150.73K |
| Jul 27, 2026 | $10.99 | $11.56 | $10.99 | $11.45 | 46.52K |
| Jul 24, 2026 | $11.056 | $11.34 | $10.7901 | $10.80 | 35.9K |
| Jul 23, 2026 | $10.83 | $11.17 | $10.70 | $11.00 | 71.86K |
| Jul 22, 2026 | $11.47 | $11.50 | $10.81 | $11.02 | 92.05K |
| Jul 21, 2026 | $11.21 | $11.755 | $11.16 | $11.50 | 136.99K |
| Jul 20, 2026 | $11.68 | $11.68 | $11.29 | $11.33 | 31.77K |
| Jul 17, 2026 | $11.68 | $11.95 | $11.32 | $11.66 | 65.47K |
| Jul 16, 2026 | $11.08 | $12.12 | $10.7484 | $11.82 | 130.68K |
The latest Smart Investors Daily articles mentioning CARL.
CARL research
Company profile and research snapshot.
Carlsmed Inc is a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. It is focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of AI-enabled software solutions, and interbody implants that it custom design for each patient's unique pathology and vertebral bone topography, and single-use surgical instruments. The Company designs, manufactures, and markets aprevo, a comprehensive technology platform for spine fusion surgery procedures.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Truist Securities | Buy | — |
| Jul 1, 2026 | Needham | Buy | — |
| May 6, 2026 | BTIG | Buy | — |
| Apr 15, 2026 | Truist Securities | Buy | — |
| Apr 9, 2026 | Goldman Sachs | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Aug 12, 2026
Carlsmed, Inc. (CARL) Bank of America SMID Cap Virtual Conference August 12, 2026 11:00 AM EDTCompany ParticipantsMichael Cordonnier - Co-Founder, Chairman,...
Benzinga · Aug 6, 2026
Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $18 to $20.
SeekingAlpha · Aug 5, 2026
Carlsmed, Inc. (CARL) Q2 2026 Earnings Call August 5, 2026 4:30 PM EDTCompany ParticipantsStephanie Zhadkevich - VP & Head of Investor RelationsMichael...
Benzinga · Aug 5, 2026
Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $72.000 million-$77.000 million to $74.000 million-$78.000 million vs $74.830 million estimate.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CARL.
